You are here

Talzenna

Pfizer's Talzenna snags broader prostate cancer nod than AstraZeneca and Merck's rival PARP med

Pfizer's Talzenna snags broader prostate cancer nod than AstraZeneca and Merck's rival PARP med

Fierce Pharma

prostate cancer

PARP inhibitors

Flag link:

Pfizer’s PARP inhibitor combo treatment passes primary endpoint — but details are slim

Pfizer’s PARP inhibitor combo treatment passes primary endpoint — but details are slim

Endpoints

PARP inhibitors

clinical trials

prostate cancer

Flag link:

ASCO-GU – prostate cancer PARPS move to the front line

ASCO-GU – prostate cancer PARPS move to the front line

EP Vantage

prostate cancer

PARP inhibitors

Clovis Oncology

Flag link:

Pfizer's PARP, androgen inhibitors next combo partners for NKTR-214

Pfizer's PARP, androgen inhibitors next combo partners for NKTR-214

BioCentury

Nektar Therapeutics

prostate cancer

Flag link:

Can Pfizer's new breast cancer drug Talzenna really make a dent in the PARP field?

Can Pfizer's new breast cancer drug Talzenna really make a dent in the PARP field?

Fierce Pharma

PARP inhibitors

Flag link: